THERAVANCE, INC. COMMON STOCK PURCHASE AGREEMENT July 30, 2013Common Stock Purchase Agreement • July 30th, 2013 • Theravance Inc • Pharmaceutical preparations • Delaware
Contract Type FiledJuly 30th, 2013 Company Industry JurisdictionTHIS COMMON STOCK PURCHASE AGREEMENT (the “Agreement”) is made as of the 30th day of July, 2013, by and among Theravance, Inc., a Delaware corporation (the “Company”), Glaxo Group Limited, a limited liability company organized under the laws of England and Wales (the “Investor”), and solely for the purposes of Sections 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.9, 6.10, 6.11, 6.12, 6.13, 6.14, 6.17 and 6.18 hereof, GlaxoSmithKline LLC, a Delaware limited liability company, the successor entity to SmithKline Beecham Corporation, a Pennsylvania corporation (“GSK”).
THERAVANCE, INC. COMMON STOCK PURCHASE AGREEMENT [date]Common Stock Purchase Agreement • May 4th, 2011 • Theravance Inc • Pharmaceutical preparations • Delaware
Contract Type FiledMay 4th, 2011 Company Industry JurisdictionTHIS COMMON STOCK PURCHASE AGREEMENT (the “Agreement”) is made as of the day of , by and among Theravance, Inc., a Delaware corporation (the “Company”), Glaxo Group Limited, a limited liability company organized under the laws of England and Wales (the “Investor”), and solely for the purposes of Sections 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.9, 6.10, 6.11, 6.12, 6.13, 6.14, 6.17 and 6.18 hereof, GlaxoSmithKline LLC, a Delaware limited liability company, the successor entity to SmithKline Beecham Corporation, a Pennsylvania corporation (“GSK”).